Protara Therapeutics, Inc. (TARA)
| Previous close | 2.7300 |
| Open | 2.7600 |
| Bid | 2.6700 x 100 |
| Ask | 2.8500 x 100 |
| Day's range | 2.7300 - 2.8900 |
| 52-week range | 1.0400 - 5.2400 |
| Volume | |
| Avg. volume | 233,893 |
| Market cap | 31.329M |
| Beta (5Y monthly) | 1.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.5700 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 27.00 |
GlobeNewswireProtara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2026NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has entered into a subscription agreement for the sale of an aggregate of 9,143,380 shares of its common stock (Shares) or, for certain purchasers, pre-funded warrants
- GlobeNewswire
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
New development pathway significantly expands addressable patient population for IV Choline ChlorideIV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S.Approximately 80% of PN patients are choline deficient, which can lead to liver damage and hepatic failure; ASPEN recommends choline replacement for PN patientsCompany expects to start registrational trial to support FDA approval of IV Choline Chloride for PN patie
- GlobeNewswire
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
TARA-002 demonstrated a complete response rate of 43% at three months in BCG-Unresponsive/Experienced patients in ongoing NMIBC programTARA-002 demonstrated a complete response rate of 63% at three months in CIS-only patients in ongoing NMIBC programTARA-002 demonstrated a favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse eventsPreliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC expected in 2H 2024 NEW YORK, Apr
